Morpholine → N-((3-chloropyrazin-2-yl)methyl)-4-morpholinocyclohexanecarboxamide
反応式
[Cl:1][C:2]1[C:3]([CH2:8][NH:9][C:10]([CH:12]2[CH2:17][CH2:16][C:15](=O)[CH2:14][CH2:13]2)=[O:11])=[N:4][CH:5]=[CH:6][N:7]=1.[NH:19]1[CH2:24][CH2:23][O:22][CH2:21][CH2:20]1>>[Cl:1][C:2]1[C:3]([CH2:8][NH:9][C:10]([CH:12]2[CH2:17][CH2:16][CH:15]([N:19]3[CH2:24][CH2:23][O:22][CH2:21][CH2:20]3)[CH2:14][CH2:13]2)=[O:11])=[N:4][CH:5]=[CH:6][N:7]=1参加物
3
実験手順
According to the procedure described in example 7 step 7a N-((3-chloropyrazin-2-yl)methyl)-4-oxocyclohexanecarboxamide (1 g) and morpholine (0.44 mL) gave after work-up N-((3-chloropyrazin-2-yl)methyl)-4-morpholinocyclohexanecarboxamide (1.28 g). This crude product was used in the next step without further purification.
出典と根拠
- ORDレコード
- ord-a99c7b8e5467417da344e96eac4442dc
- 出典データセット
- uspto-grants-2014_02
- 特許番号
- US08658794B2